Efficacy, Safety, and Tolerability of Halobetasol Propionate 0.01%-Tazarotene 0.045% Lotion for Moderate to Severe Plaque Psoriasis in the Hispanic Population: Post Hoc Analysis

Topical corticosteroids are the mainstay of psoriasis treatment; however, safety concerns often limit their use. Combination therapy with tazarotene (TAZ) may optimize efficacy, minimizing safety and tolerability concerns. Although psoriasis affects a diverse patient population, data on the efficacy and safety of topical therapies for the treatment of psoriasis in Hispanic patients are sparse. This post hoc analysis investigated the efficacy, safety, and tolerability of once-daily application, fixed-combination halobetasol propionate (HP) 0.01%-TAZ 0.045% lotion in Hispanic participants with moderate to severe plaque psoriasis. Rapid and sustained reductions in disease severity were found in the Hispanic population treated with HP/TAZ lotion with good tolerability and safety over 8 weeks.